Ecor1 Capital, Llc Purchases 6,646 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) Stock

AnaptysBio, Inc. (NASDAQ:ANAB) Director Ecor1 Capital, Llc bought 6,646 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was acquired at an average price of $12.95 per share, for a total transaction of $86,065.70. Following the completion of the purchase, the director now directly owns 7,880,094 shares in the company, valued at approximately $102,047,217.30. The trade was a 0.08 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Monday, December 30th, Ecor1 Capital, Llc acquired 65,184 shares of AnaptysBio stock. The shares were bought at an average price of $12.92 per share, for a total transaction of $842,177.28.

AnaptysBio Trading Up 9.3 %

Shares of ANAB opened at $14.60 on Friday. AnaptysBio, Inc. has a 1-year low of $12.51 and a 1-year high of $41.31. The firm has a market capitalization of $444.26 million, a price-to-earnings ratio of -2.40 and a beta of -0.11. The firm’s 50-day moving average price is $19.75 and its 200-day moving average price is $28.43.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The firm had revenue of $30.02 million during the quarter, compared to analyst estimates of $7.92 million. On average, research analysts forecast that AnaptysBio, Inc. will post -6.02 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on ANAB shares. JPMorgan Chase & Co. lowered their price target on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a research report on Thursday, December 19th. Wells Fargo & Company reduced their price target on AnaptysBio from $56.00 to $40.00 and set an “overweight” rating on the stock in a research report on Thursday, December 12th. HC Wainwright downgraded AnaptysBio from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $52.00 to $19.00 in a research report on Wednesday, December 11th. Wedbush restated an “outperform” rating and issued a $40.00 target price (down previously from $42.00) on shares of AnaptysBio in a report on Wednesday, December 11th. Finally, Guggenheim decreased their target price on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, December 12th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, AnaptysBio has a consensus rating of “Moderate Buy” and a consensus target price of $41.45.

Institutional Trading of AnaptysBio

A number of hedge funds have recently modified their holdings of the business. Values First Advisors Inc. purchased a new position in AnaptysBio during the 3rd quarter valued at about $49,000. nVerses Capital LLC increased its stake in shares of AnaptysBio by 700.0% during the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 1,400 shares in the last quarter. Headlands Technologies LLC lifted its holdings in shares of AnaptysBio by 444.8% during the second quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock valued at $89,000 after purchasing an additional 2,900 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of AnaptysBio by 81.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 2,600 shares in the last quarter. Finally, Point72 DIFC Ltd grew its stake in shares of AnaptysBio by 680.5% in the 3rd quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock worth $205,000 after buying an additional 5,342 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.